Bristol-Myers Squibb Company (BMY) Announces Plans For Third Quarter Submission Of A Biologics License Application For Opdivo® (Nivolumab), An Investigational PD-1 Immune Checkpoint Inhibitor, For Previously Treated Advanced Melanoma
7/10/2014 10:03:51 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMS) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S.
Help employers find you! Check out all the jobs and post your resume.
comments powered by